Filing Details

Accession Number:
0001214659-23-003941
Form Type:
13D Filing
Publication Date:
2023-03-16 20:00:00
Filed By:
Tang Capital Partners Lp
Company:
Jounce Therapeutics Inc.
Filing Date:
2023-03-17
SEC Url:
13D Filing
Ownership Summary

Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
TANG CAPITAL PARTNERS 0 5,300,087 0 5,300,087 5,300,087 10.2%
TANG CAPITAL MANAGEMENT 0 5,300,087 0 5,300,087 5,300,087 10.2%
KEVIN TANG 0 5,300,087 0 5,300,087 5,300,087 10.2%
Concentra Biosciences 0 0 0 0 0 0%
Filing

 

 

SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

 

 

SCHEDULE 13D/A

 

 

Under the securities exchange act of 1934
(amendment no. 1)*

 

 

Jounce Therapeutics, Inc.
(Name of Issuer)

 

Common Stock, par value $0.001 per share
(Title of Class of Securities)

 

 

481116101
(CUSIP Number)

 

 

Ryan A. Murr
James J. Moloney
Gibson, Dunn & Crutcher LLP
555 Mission Street, Suite 3000
San Francisco, CA 94105
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)

 

 

March 17, 2023
(Date of Event Which Requires Filing of This Statement)

 

 

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. x

 

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 
   
 

 

CUSIP No. 481116101
1

NAMES OF REPORTING PERSONS

 

TANG CAPITAL PARTNERS, LP

 

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

(a) o

 

(b) o

 

3 SEC USE ONLY
4

SOURCE OF FUNDS (SEE INSTRUCTIONS)

 

WC

 

5 CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E) ¨
6

CITIZENSHIP OR PLACE OF ORGANIZATION

 

DELAWARE

 

NUMBER OF
SHARES

BENEFICIALLY

OWNED BY
EACH REPORTING

PERSON WITH

7

SOLE VOTING POWER

 

0

 

8

SHARED VOTING POWER

 

5,300,087

 

9

SOLE DISPOSITIVE POWER

 

0

 

10

SHARED DISPOSITIVE POWER

 

5,300,087

 

11

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

5,300,087

 

12

CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

 

o

 

13

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11

 

10.2%

 

14

TYPE OF REPORTING PERSON

 

PN

 

 

   
 

 

CUSIP No. 481116101
1

NAMES OF REPORTING PERSONS

 

TANG CAPITAL MANAGEMENT, LLC

 

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

(a) o

 

(b) o

 

3 SEC USE ONLY
4

SOURCE OF FUNDS (SEE INSTRUCTIONS)

 

WC

 

5 CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E) ¨
6

CITIZENSHIP OR PLACE OF ORGANIZATION

 

DELAWARE

 

NUMBER OF
SHARES

BENEFICIALLY

OWNED BY
EACH REPORTING

PERSON WITH

7

SOLE VOTING POWER

 

0

 

8

SHARED VOTING POWER

 

5,300,087

 

9

SOLE DISPOSITIVE POWER

 

0

 

10

SHARED DISPOSITIVE POWER

 

5,300,087

 

11

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

5,300,087

 

12

CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

 

o

 

13

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11

 

10.2%

 

14

TYPE OF REPORTING PERSON

 

OO

 

 

   
 

 

CUSIP No. 481116101
1

NAMES OF REPORTING PERSONS

 

KEVIN TANG

 

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

(a) o

 

(b) o

 

3 SEC USE ONLY
4

SOURCE OF FUNDS (SEE INSTRUCTIONS)

 

WC

 

5 CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E) ¨
6

CITIZENSHIP OR PLACE OF ORGANIZATION

 

UNITED STATES

 

NUMBER OF
SHARES

BENEFICIALLY

OWNED BY
EACH REPORTING

PERSON WITH

7

SOLE VOTING POWER

 

0

 

8

SHARED VOTING POWER

 

5,300,087

 

9

SOLE DISPOSITIVE POWER

 

0

 

10

SHARED DISPOSITIVE POWER

 

5,300,087

 

11

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

5,300,087

 

12

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

 

o

 

13

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11

 

10.2%

 

12

TYPE OF REPORTING PERSON

 

IN

 

 

   
 

 

CUSIP No. 481116101
1

NAMES OF REPORTING PERSONS

 

Concentra Biosciences, LLC

 

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

(a) o

 

(b) o

 

3 SEC USE ONLY
4

SOURCE OF FUNDS (SEE INSTRUCTIONS)

 

 

 

5 CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E) ¨
6

CITIZENSHIP OR PLACE OF ORGANIZATION

 

UNITED STATES

 

NUMBER OF
SHARES

BENEFICIALLY

OWNED BY
EACH REPORTING

PERSON WITH

7

SOLE VOTING POWER

 

0

 

8

SHARED VOTING POWER

 

0

 

9

SOLE DISPOSITIVE POWER

 

0

 

10

SHARED DISPOSITIVE POWER

 

0

 

11

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

0

 

12

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

 

o

 

13

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11

 

0%

 

12

TYPE OF REPORTING PERSON

 

OO

 

 

   
 

 

Explanatory Note

 

This Schedule 13D/A relates to the common stock, par value $0.001 (the “Common Stock”), of Jounce Therapeutics, Inc., a Delaware corporation (the “Issuer”) and amends the Schedule 13D filed on March 14, 2023 (as amended, the “Statement” or “Schedule 13D”). Capitalized terms used and not defined in this Amendment No. 1 have the meanings set forth in the Schedule 13D.

 

This Amendment No. 1 is being filed to amend Item 4 of the Schedule 13D as set forth below.

 

Item 4.Purpose of Transaction

 

Item 4 of the Schedule 13D is amended by adding the following:

 

On March 15, 2023, the Reporting Persons entered into a mutual confidentiality agreement with the Issuer.

 

On March 17, 2023, Concentra delivered a letter to the Issuer extending the expiration date for the acquisition proposal to midnight eastern time on March 26, 2023 (see Exhibit 3).

 

Item 7.Material to Be Filed as Exhibits

 

Exhibit 1:     Joint Filing Agreement by and among the Reporting Persons (previously filed)

 

Exhibit 2:     Acquisition Proposal, dated March 14, 2023, sent from Concentra to the Issuer (previously filed)

 

Exhibit 3:     Acquisition Proposal Extension, dated March 17, 2023, sent from Concentra to the Issuer

 

   
 

 

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Date: March 17, 2023  

 

TANG CAPITAL PARTNERS, LP  
     
By:  Tang Capital Management, LLC, its General Partner  
     
By: /s/ Kevin Tang  
Kevin Tang, Manager  
     
     
TANG CAPITAL MANAGEMENT, LLC  
     
By: /s/ Kevin Tang  
Kevin Tang, Manager  
     
/s/ Kevin Tang  
Kevin Tang  
     
CONCENTRA BIOSCIENCES, LLC  
     
By: /s/ Kevin Tang  
Kevin Tang, Chief Executive Officer  

 

   
 

 

EXHIBIT 3

 

Concentra Biosciences, LLC

4747 Executive Drive, Suite 210 | San Diego, CA 92121

 

 

 

March 17, 2023

 

 

Richard Murray

Chief Executive Officer
Jounce Therapeutics, Inc.
780 Memorial Drive

Cambridge, Massachusetts 02139

 

Re:      Acquisition Proposal Extension

 

Dear Richard:

 

As we have now entered into a mutual confidentiality agreement and commenced confirmatory due diligence, we hereby extend the expiration date for our acquisition proposal to midnight eastern time on March 26, 2023.

 

We look forward to continuing our constructive dialogue and are hopeful that we can enter into definitive agreements shortly.

 

  Sincerely,
   
  Kevin Tang
  Chief Executive Officer